重度哮喘患者死亡率:NORDSTAR队列研究结果
重度哮喘全因死亡率显著高于轻中度哮喘,20年累积死亡率34%对20%,主要归因于呼吸系统疾病死亡,口服糖皮质激素使用和2型炎症标志物为 contributing 死亡风险因素。
要点
- 重度哮喘20年累积死亡率为34%,显著高于轻中度哮喘的20%。
- 全因死亡风险增加主要由呼吸系统疾病死亡驱动(12.6%对3.3%)。
- 口服糖皮质激素使用和2型炎症标志物可部分解释死亡风险增加。
核心结论
- 重度哮喘与显著增高的全因死亡风险相关,主要归因于呼吸系统疾病死亡。
- 口服糖皮质激素使用和2型炎症标志物是 contributing 死亡风险因素。
研究设计与样本
- 基于丹麦NORDSTAR研究协作平台注册数据的回顾性队列研究。
- 排除纳入前已诊断COPD的患者。
主要发现
- 20年随访累积全因死亡率为重度哮喘34%(95%CI 32-35%)对轻中度哮喘20%(95%CI 19-20%),p<0.001。
- 全因死亡风险比(HR)为1.99(95%CI 1.90-2.09),p<0.001。
- 调整口服糖皮质激素使用后HR为1.30(95%CI 1.23-1.37),p<0.001;调整2型炎症标志物后HR为1.34(95%CI 1.09-1.64),p<0.001。
- 呼吸系统疾病累积死亡率为12.6%(95%CI 11.7-13.6%)对3.3%(95%CI 3.2-3.5%),p<0.001;癌症为7.5%(95%CI 6.8-8.3%)对5.9%(95%CI 5.7-6.2%),p<0.001;心血管疾病为4.7%(95%CI 4.1-5.3%)对3.8%(95%CI 3.6-4.0%),p<0.001。
- 哮喘相关死亡的相对风险为三倍(HR 2.95,95%CI 2.08-4.18),p<0.001。
临床怎么用
- 对重度哮喘患者应关注全因死亡风险,尤其是呼吸系统疾病死亡风险。
- 口服糖皮质激素使用和2型炎症标志物可帮助识别死亡风险较高的重度哮喘患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Longitudinal data addressing the impact of asthma severity on mortality are lacking. We aimed to explore all-cause and cause-specific mortality according to asthma severity. METHODS: The present registry-based cohort study is based on Danish data from the NORdic Dataset for aSThmA Research (NORDSTAR) research collaboration platform. Adult patients with severe asthma were matched on age and sex to 10 patients with mild-to-moderate asthma and followed from 2000 to 2020. Patients with COPD diagnosed prior to inclusion were excluded. Absolute and relative measures of all-cause and cause-specific mortality were compared between severe and mild-to-moderate asthma. RESULTS: We included 11 881 and 118 810 patients with severe and mild-to-moderate asthma, respectively. All-cause mortality was significantly higher in patients with severe asthma compared to patients with mild-to-moderate asthma, both in absolute measures of the cumulative mortality (34% (95% CI 32-35%) versus 20% (95% CI 19-20%); p<0.001) after 20 years of follow-up and in relative measures (hazard ratio (HR) 1.99, 95% CI 1.90-2.09; p<0.001). The HR of all-cause mortality was attenuated after adjustment for oral corticosteroid (OCS) use (HR 1.30, 95% CI 1.23-1.37; p<0.001) and type 2 (T2) inflammatory markers (HR 1.34, 95% CI 1.09-1.64; p<0.001). The increased cumulative mortality risk was mainly due to respiratory diseases (12.6% (95% CI 11.7-13.6%) versus 3.3% (95% CI 3.2-3.5%); p<0.001), with cancer (7.5% (95% CI 6.8-8.3%) versus 5.9% (95% CI 5.7-6.2%); p<0.001) and cardiovascular diseases (4.7% (95% CI 4.1-5.3%) versus 3.8% (95% CI 3.6-4.0%); p<0.001) also contributing. Although rare, the relative risk of asthma-related deaths was three-fold in severe asthma patients (HR 2.95, 95% CI 2.08-4.18; p<0.001). CONCLUSIONS: In this nationwide cohort, severe asthma was associated with a significantly higher mortality risk compared to mild-to-moderate asthma. The increased risk was primarily driven by respiratory-related deaths, with OCS use and T2 inflammation as contributing mortality risk factors.
引用
- Hansen S, von Bülow A, Cooper A, et al. Mortality in severe asthma: results from the NORDSTAR cohort. Eur Respir J. 2026. PMID: 41198390. doi:10.1183/13993003.01289-2025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。